Study wrapper · #165
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.
Editor's note
This is a narrative review of incretin-based therapies for adolescent obesity, spanning single (GLP-1RA), dual (tirzepatide), and triple (retatrutide) agonists. Its most concrete data point is from the STEP TEENS trial, where once-weekly semaglutide was associated with roughly 16% mean body-weight reduction over 68 weeks in adolescents; liraglutide produced more modest reductions. For tirzepatide and triple agonists, the authors are careful to note that paediatric data are limited or unavailable and that adult results were extrapolated cautiously. Gastrointestinal effects were the most common adverse events across agents. As a narrative (non-systematic) review, this synthesises rather than pools evidence and reflects author selection. The appropriately hedged bottom line: GLP-1RAs show clinically meaningful weight reduction in adolescents, but multi-receptor agonists need dedicated paediatric trials on long-term safety, development, and adherence before broader use. Weigh it as a balanced landscape overview, strongest where it cites STEP TEENS.
Plain-language abstract
This review looked at medications based on the gut hormone GLP-1 for treating obesity in teenagers, covering drugs that act on one receptor (like semaglutide and liraglutide), two receptors (tirzepatide), or three (retatrutide). Lifestyle changes remain the first approach, but their long-term results are limited, prompting interest in medications. The clearest evidence came from the STEP TEENS trial, where weekly semaglutide was associated with about 16% average weight reduction over 68 weeks in adolescents; liraglutide produced smaller reductions. For tirzepatide and newer triple-action drugs, the authors stress that data in children and teens are limited or missing, so results from adults were applied only cautiously. Across all these drugs, stomach-and-gut symptoms were the most common side effects. The authors conclude that GLP-1 medications are a meaningful option for adolescent obesity, but that multi-receptor drugs need well-designed studies in young people — on long-term safety, growth and development, and real-world use — before wider adoption.